This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Michaelson, M. D. Articles by Smith, M. R. Search for Related Content PubMed PubMed Citation Articles by Michaelson, M. D. Articles by Smith, M. R. Related Articles Related Editorial Related Correspondence Social Bookmarking                            What's this?

Randomized Controlled Trial of Annual Zoledronic Acid to Prevent Gonadotropin-Releasing Hormone Agonist–Induced Bone Loss in Men With Prostate Cancer

M. Dror Michaelson, Donald S. Kaufman, Hang Lee, Francis J. McGovern, Philip W. Kantoff, Mary Anne Fallon, Joel S. Finkelstein, Matthew R. Smith

From the Division of Hematology and Oncology and Endocrine Unit, Department of Medicine, Department of Urology, and Biostatistics Center, Massachusetts General Hospital; and the Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, MA

Address reprint requests to Matthew R. Smith, MD, Massachusetts General Hospital, Department of Hematology/ Oncology, 100 Blossom St, Cox 640, Boston, MA 02114; e-mail: smith.matthew{at}mgh.harvard.edu

Purpose Gonadotropin-releasing hormone (GnRH) agonists decrease bone mineral density (BMD) and increase fracture risk in men with prostate cancer. Annual zoledronic acid increases BMD in postmenopausal women, but its efficacy in hypogonadal men is not known.

Patients and Methods In a 12-month study, 40 men with nonmetastatic prostate cancer who were receiving a GnRH agonist and had T scores more than –2.5 were randomly assigned to zoledronic acid (4 mg intravenously on day 1 only) or placebo. BMD of the posteroanterior lumbar spine and proximal femur were measured by dual-energy x-ray absorptiometry.

Results Mean (± SE) BMD of the posteroanterior lumbar spine decreased by 3.1% ± 1.0% in men assigned to placebo and increased by 4.0% ± 1.0% in men assigned to zoledronic acid (P < .001). BMD of the total hip decreased by 1.9% ± 0.7% in men assigned to placebo and increased by 0.7% ± 0.5% in men assigned to zoledronic acid (P = .004). Similar between-group differences were observed for the femoral neck and trochanter. Serum N-telopeptide, a marker of osteoclast activity, decreased significantly after zoledronic acid treatment.

Conclusion In men receiving a GnRH agonist, a single treatment with zoledronic acid significantly increased BMD and durably suppressed serum N-telopeptide levels for 12 months. Annual zoledronic acid may be a convenient and effective strategy to prevent bone loss in hypogonadal men.

Supported by the W. Bradford Ingalls Foundation and research awards from the Prostate Cancer Foundation and Novartis Oncology.

The study sponsors played no role in the study design; in collection, analysis, and interpretation of data; or in writing of this report.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Editorial

• Annual Zoledronic Acid: Is Less More?
  Celestia S. Higano
  JCO 2007 25: 1026 [Full Text]

Related Correspondence

• Patient Quality of Life Safeguarding: The Primary Aim in Nonmetastatic Prostate Cancer Patients
  Tommaso Cai and Riccardo Bartoletti
  JCO 2007 25: 3385 [Full Text]

This article has been cited by other articles:

				M. R. Smith, B. Egerdie, N. H. Toriz, R. Feldman, T. L.J. Tammela, F. Saad, J. Heracek, M. Szwedowski, C. Ke, A. Kupic, et al. Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer N. Engl. J. Med., August 20, 2009; 361(8): 745 - 755. [Abstract] [Full Text] [PDF]

				T. Van den Wyngaert, M. T. Huizing, E. Fossion, and J. B. Vermorken Bisphosphonates in Oncology: Rising Stars or Fallen Heroes Oncologist, February 1, 2009; 14(2): 181 - 191. [Abstract] [Full Text] [PDF]

				F. Saad, J. D. Adachi, J. P. Brown, L. A. Canning, K. A. Gelmon, R. G. Josse, and K. I. Pritchard Cancer Treatment-Induced Bone Loss in Breast and Prostate Cancer J. Clin. Oncol., November 20, 2008; 26(33): 5465 - 5476. [Abstract] [Full Text] [PDF]

				F. R. SINGER and D. R. EYRE Using biochemical markers of bone turnover in clinical practice Cleveland Clinic Journal of Medicine, October 1, 2008; 75(10): 739 - 750. [Abstract] [Full Text] [PDF]

				J. R. Berenson, O. Yellin, R. V. Boccia, M. Flam, S.-F. Wong, O. Batuman, M. M. Moezi, D. Woytowitz, H. Duvivier, Y. Nassir, et al. Zoledronic Acid Markedly Improves Bone Mineral Density for Patients with Monoclonal Gammopathy of Undetermined Significance and Bone Loss Clin. Cancer Res., October 1, 2008; 14(19): 6289 - 6295. [Abstract] [Full Text] [PDF]

				M. R. Smith Osteoporosis in Men With Prostate Cancer: Now for the Fracture Data J. Clin. Oncol., September 20, 2008; 26(27): 4371 - 4372. [Full Text] [PDF]

				S. L. Greenspan, J. B. Nelson, D. L. Trump, J. M. Wagner, M. E. Miller, S. Perera, and N. M. Resnick Skeletal Health After Continuation, Withdrawal, or Delay of Alendronate in Men With Prostate Cancer Undergoing Androgen-Deprivation Therapy J. Clin. Oncol., September 20, 2008; 26(27): 4426 - 4434. [Abstract] [Full Text] [PDF]

				M. T. Drake, B. L. Clarke, and S. Khosla Bisphosphonates: Mechanism of Action and Role in Clinical Practice Mayo Clin. Proc., September 1, 2008; 83(9): 1032 - 1045. [Abstract] [Full Text] [PDF]

				M. D. Michaelson, S. E. Cotter, P. C. Gargollo, A. L. Zietman, D. M. Dahl, and M. R. Smith Management of Complications of Prostate Cancer Treatment CA Cancer J Clin, July 1, 2008; 58(4): 196 - 213. [Abstract] [Full Text] [PDF]

				M. Aapro, P. A. Abrahamsson, J. J. Body, R. E. Coleman, R. Colomer, L. Costa, L. Crino, L. Dirix, M. Gnant, J. Gralow, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel Ann. Onc., March 1, 2008; 19(3): 420 - 432. [Abstract] [Full Text] [PDF]

				S. L. Greenspan Approach to the Prostate Cancer Patient with Bone Disease J. Clin. Endocrinol. Metab., January 1, 2008; 93(1): 2 - 7. [Abstract] [Full Text] [PDF]

				J. E. Brown, S. P. Ellis, J. E. Lester, S. Gutcher, T. Khanna, O.-P. Purohit, E. McCloskey, and R. E. Coleman Prolonged Efficacy of a Single Dose of the Bisphosphonate Zoledronic Acid Clin. Cancer Res., September 15, 2007; 13(18): 5406 - 5410. [Abstract] [Full Text] [PDF]

				T. Cai and R. Bartoletti Patient Quality of Life Safeguarding: The Primary Aim in Nonmetastatic Prostate Cancer Patients J. Clin. Oncol., August 1, 2007; 25(22): 3385 - 3385. [Full Text] [PDF]

				M. D. Michaelson and M. R. Smith In Reply J. Clin. Oncol., August 1, 2007; 25(22): 3385 - 3386. [Full Text] [PDF]

				Zoledronic Acid During GnRH Therapy for Prostate Cancer Journal Watch Oncology and Hematology, April 9, 2007; 2007(409): 2 - 2. [Full Text]

				C. S. Higano Annual Zoledronic Acid: Is Less More? J. Clin. Oncol., March 20, 2007; 25(9): 1026 - 1026. [Full Text] [PDF]